A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Naive HIV-1 Infected Subjects

Trial Profile

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Naive HIV-1 Infected Subjects

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DRIVE-AHEAD
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Jul 2017 Results from this trial have been presented at the 9th International Conference on HIV Science (IAS 2017) according to a Merck AG media release.
    • 25 Jul 2017 Results published in a Merck AG media release.
    • 25 Jul 2017 Primary endpoint (Proportion of participants with HIV-1 RNA 50 copies/mL at Week 48) has been met, according to a Merck AG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top